ADDF launches new phase of $150m Alzheimer’s diagnostics accelerator
The Alzheimer’s Drug Discovery Foundation (ADDF) has launched the third phase of its Diagnostics Accelerator (DxA) in New York, fueled by an additional $50 million investment, bringing the initiative’s total funding to $150 million. Co-founded by Leonard A. Lauder and Bill Gates, DxA 3.0 will prioritize advancements in blood tests for tau and other co-pathologies, alongside AI-driven biomarkers and integrated multi-marker panels aimed at enhancing drug development and prevention strategies.
This phase is particularly significant as it reflects renewed commitments from key industry players, including Biogen and Eli Lilly, while also attracting new support from organizations like the JTMF Foundation. Since its inception, DxA has invested $100 million in 76 programs globally, contributing to the FDA approval of a blood test for Alzheimer’s in 2025. The focus on ultra-sensitive assays and digital biomarkers could significantly improve detection and monitoring of neurodegenerative diseases.
For professionals in the longevity and healthspan research fields, the implications of DxA’s advancements are profound. This initiative not only accelerates the path to effective therapies but also sets a precedent for integrating diagnostics into comprehensive treatment strategies. I encourage you to explore the full article for deeper insights into this pivotal development.